Meeting
2022 ASCO Annual Meeting
Characteristics of long-surviving patients with multiple myeloma: Over 12 years of follow-up in the Connect MM Registry.
Authors
Howard R. Terebelo
Providence Cancer Institute, Southfield, MI
Howard R. Terebelo , James Omel , Lynne I. Wagner , James W. Hardin , Robert M. Rifkin , Sikander Ailawadhi , Brian G. Durie , Mohit Narang , Kathleen Toomey , Cristina J. Gasparetto , Prashant Ramesh Joshi , Edward Yu , E. Dawn Flick , Weiyuan Chung , Hans C. Lee , Rafat Abonour , Sundar Jagannath
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies
Sub Track
Multiple Myeloma
Clinical Trial Registration Number
NCT01081028
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 8027)
DOI
10.1200/JCO.2022.40.16_suppl.8027
Abstract #
8027
Poster Bd #
451
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Real-world treatment patterns, healthcare resource utilization (HRU), and costs of initial line of therapy (LOT1) in multiple myeloma (MM).
First Author: Stacey DaCosta Byfield
Poster
2020 ASCO Virtual Scientific Program
Bortezomib, lenalidomide, and dexamethasone (VRD) is superior to lenalidomide, adriamycin, and dexamethasone (RAD) prior to risk-adapted transplant in newly diagnosed myeloma.
First Author: Stefan Knop
First Author: George Somlo
Poster
2013 ASCO Annual Meeting
Early versus delayed autologous stem cell transplant (ASCT) in patients receiving induction therapy with lenalidomide, bortezomib, and dexamethasone (RVD) for newly diagnosed multiple myeloma (MM).
First Author: Ajay K. Nooka